SWK Holdings Corporation Announces Financial Results for Fourth Quarter and Full-Year 2020

Corporate Highlights
Closed four transactions in 2020 deploying $34.8 million; additional $8.1 million deployed to existing borrowers
Income producing assets as of December 31, 2020 reached an all-time high of $206.0 million, accompanied by strong credit trends
Closed a $9.0 million transaction in March 2021, deploying $7.1 million
Received two milestone payments from Cara Therapeutics totaling $5.0 million, with SWK retaining $3.0 million and the other $2.0 million being remitted to Enteris' prior owner. 
Specialty Finance Segment Highlights:
For the fourth quarter of 2020, finance portfolio realized yield was 16.6%, compared to 20.4% for the fourth quarter of 2019
For the fourth quarter of 2020, finance portfolio effective yield was 13.8%, a 60 bps increase compared with 13.2% in the fourth quarter of 2019

Related Keywords

United States ,Dallas ,Texas ,Enteris Biopharma ,Rajiv Khosla ,Flowonix Medical Inc ,Alimera Sciences Inc ,Holdings Corporation ,Sincerus Pharmaceuticals Inc ,Eyepoint Pharmaceuticals Inc ,Holdings Corporation Nasdaq ,Cara Therapeutics ,Finance Segment Highlights ,Winston Black ,Sincerus Pharmaceuticals ,Eyepoint Pharmaceuticals ,Alimera Sciences ,Trio Healthcare ,Flowonix Medical ,Year Ended ,Investors Events ,Swk Holdings Corporation ,ஒன்றுபட்டது மாநிலங்களில் ,டல்லாஸ் ,டெக்சாஸ் ,ராஜீவ் கோசில ,ஹோல்டிங்ஸ் நிறுவனம் ,ஹோல்டிங்ஸ் நிறுவனம் நாஸ்டாக் ,காரா சிகிச்சை ,நிதி பிரிவு சிறப்பம்சங்கள் ,வின்ஸ்டன் கருப்பு ,மூவரும் சுகாதாரம் ,முதலீட்டாளர்கள் நிகழ்வுகள் ,